ClinicalTrials.gg
TerminatedNCT01100879AOC-MMUpdated May 9, 2022

Ferric Carboxymaltose for Treatment of Anaemia of Cancer in Subjects With Multiple Myeloma Receiving Chemotherapy

A Phase 4 interventional study of Ferric carboxymaltose in Iron-Deficiency Anemia, sponsored by Vifor Pharma. Terminated at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-05-09.

Sponsored by Vifor Pharma (part of CSL Limited) · Phase 4, Interventional, and Treatment

Why this study was terminated
Lack of Recruitment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
3
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 57 studies testing ferric carboxymaltose in Anemia, Iron-Deficiency — 7 open to participants now, 7 under way, none of them phase 3. ferric carboxymaltose · Anemia, Iron-Deficiency.

Enrollment
54th of 57
3 · median 100
Started
2010
with 2 others
Phase 4
24 of 57
6 open now
Registered
10th of 57
by date
Lead sponsor
7 of 57
Vifor Pharma

Among the 57 studies testing ferric carboxymaltose in Anemia, Iron-Deficiency, this one is the 54th largest by enrollment, is one of 3 that started in 2010, is one of 24 in phase 4, and was the 10th registered.

Anemia, Iron-Deficiency

601 studies on the registry are indexed under Anemia, Iron-Deficiency; 96 are open to participants now.

Browse Anemia, Iron-Deficiency studies →

Open to participants now

7 of the 57 studies testing ferric carboxymaltose in Anemia, Iron-Deficiency are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About ferric carboxymaltose

ferric carboxymaltose: first FDA approval 2013 (INJECTAFER). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Anemia, Iron-Deficiency studies recruiting now, 19 (35%) set no upper age limit and 32 (58%) stop at 75 or younger; 16 take children under 18; 17 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies testing ferric carboxymaltose in Anemia, Iron-Deficiency, or all of them as a file.
02

Study summary

Multicentre, randomised, controlled, 2-arm open-label prospective pilot study to evaluate efficacy and safety of ferric carboxymaltose (FCM) in treatment of anaemia in subjects with multiple myeloma (MM) initiating chemotherapy. The subjects will be screened for eligibility within 4 weeks prior to inclusion and randomised to receive intravenous infusions of FCM or standard care (the subjects may be treated according to the local institutional practice if requiring symptomatic management of anaemia). Thereafter the visits are scheduled at Weeks 0, 2, 4, 6 and 8.

Read the detailed description

Patients will be randomised into two groups. One will receive active FCM treatment and the other group will receive local standard of care.

Active treatment group: Subjects will receive a total dose of 1,000 mg iron as FCM on the day of the first scheduled chemotherapy cycle or within 24 hours before or after receiving chemotherapy. In subjects of weight ≤66 kg, the first dose (500 mg) will be administered on the day of the first scheduled chemotherapy cycle and the second dose (500 mg) on the next study visit.

Standard of care group: Subjects will be treated according to the local institutional practice if requiring management of symptomatic anaemia. Intravenous iron should only be used to treat absolute iron deficiency (as defined as ferritin less than the lower limit of normal based on the test reference ranges). Patients with absolute iron deficiency are not eligible for inclusion to the study.

Rescue medication to manage anaemia is permitted in both arms at the discretion of the treating physician and/or per institutional practice.

03

Conditions studied

  • Iron-Deficiency Anemia

Keywords

  • Anemia
  • Lymphoproliferative Disorders
  • Chemotherapy
  • ferric carboxymaltose
  • iron
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects (male or female) aged ≥18, suffering from a newly diagnosed or progressed/ MM and scheduled to receive anti-myeloma treatment. Progression is defined according to "Uniform Response Criteria for Multiple Myeloma"
  • Subjects with progressed/relapsed MM should have had stable disease (during the last 6 months since prior treatment).
  • at least 6 months.
  • 8.5 g/dL ≤ ≤11 g/dL at time of randomisation.
  • Iron-restricted erythropoiesis as defined:

    • Stainable iron in bone marrow (BM) combined with transferrin saturation (TSAT) ≤20%, or
    • where the evaluation of stainable iron in BM is not possible or available:
  • ferritin >30 ng/mL (women) or >40 ng/mL (men), and
  • TSAT ≤20%
  • Females of must have a negative urine pregnancy test at screening.
  • Before any study-specific procedure, the appropriate written must be obtained.

Exclusion criteria

Exclusion Criteria:

  • Any anaemia treatment within 4 weeks prior to randomisation (including red blood cell transfusions, treatment with ESA or any oral/parenteral iron preparations).
  • Anthracycline containing chemotherapy regimens.
  • Subjects weighing \<35 kg.
  • Folate deficiency (serum-folate \<4.5 nmol/L) and/or Vitamin B12 deficiency (serum-cobalamin \<145 pmol/L).
  • Ongoing haemolysis defined as serum-haptoglobin \<0.2 g/L.
  • Known chronic renal failure, \<30 mL/min/m2.
  • Recent (within last 4 weeks) significant bleeding/surgery, defined as drop in of ≥2 g/dL.
  • active inflammatory disease other than MM (according to the judgement of the Investigator).
  • Clinically relevant ongoing infectious disease including known .
  • Serum ferritin >600 ng/mL.
  • Ongoing significant neurological or psychiatric disorders including psychotic disorders or dementia.
  • Significant cardiovascular disease prior to study inclusion including myocardial infarction within 12 months prior to study inclusion, congestive heart failure Grade III or IV, or poorly controlled hypertension according to the judgment of the Investigator.
  • Elevation of liver enzymes (, alanine aminotransferase) over 3 times above the normal range or known acute hepatic disorder.
  • Subject currently is enrolled in or has not yet completed at least 30 days since ending other device or drug study(ies), or subject is receiving other investigational agent(s).
  • Subject of is evidently pregnant (e.g., positive human chorionic gonadotropin test) or is breast feeding.
  • Subject is not using adequate precautions. Adequate contraceptive precautions are defined as those which result in a low failure rate (i.e., less than 1% per year) when used consistently and correctly such as implants, injectables, combined oral contraceptives, some intra-uterine devices, sexual abstinence or vasectomised partner. Non-childbearing potential includes being surgically sterilised at least 6 months prior to the study or , defined as amenorrhea for at least 12 months.
  • Subject has known sensitivity to any of the products to be administered during dosing.
  • Subject will not be available for follow-up assessment.
  • Subject has any kind of disorder that compromises the ability of the subject to give written and/or to comply with study procedures.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
3 participants (actual)

Study arms

  • Active comparator
    Ferric carboxymaltose

    Subjects will receive a total dose of 1,000 mg iron as FCM on the day of the next scheduled chemotherapy cycle after randomisation or continuous chemotherapy. In subjects with weight ≤66 kg, the first dose iron will be 500 mg; the second dose (500 mg) will be administered on the visit 3 (week 2).

    Drug: Ferric carboxymaltose

  • No intervention
    Local standard of care.

    Subjects will be treated according to the local institutional practice.

Interventions

  • Subjects will receive a single dose of 1,000 mg iron as FCM infusion at baseline. Subjects of bw ≤66 kg will receive a single dose of 500 mg iron as FCM infusion at baseline (Week 0) and at Visit 3 (Week 2). Ferric carboxymaltose will be administered on the same day with chemotherapy treatment or within 24 hours before or after the chemotherapy. For subjects with bw ≤66 kg, if no chemotherapy planned for the visit 4 (Week 2), the second FCM dose should be infused independent of chemotherapy.

    Also known as: Ferinject

06

What researchers measure

Primary outcomes

  1. Change in haemoglobin (Hb) from baseline to Weeks 4, 6 and 8

    Mean change in Hb from baseline to Weeks 4, 6 and 8 (end of treatment) in the absence of any red cell transfusion or erythropoiesis stimulating agents (ESA) treatment.

    Time frame: week 4, 6 and 8 post baseline

Secondary outcomes

  1. Percentage of subjects with blood Hb response of at least 1 g/dL

    Percentage of subjects with blood Hb response of at least 1 g/dL in the absence of any red cell transfusion or ESA treatment.

    Time frame: 12 weeks post baseline

  2. Percentage of subjects with a blood Hb correction to at least 12 g/dL

    Percentage of subjects with a blood Hb correction to at least 12 g/dL in the absence of any red cell transfusion or ESA treatment

    Time frame: 12 weeks post baseline

  3. Time to Hb response defined as increase in Hb equal to or more than 1 g/dL

    Median time to Hb response defined as increase in Hb equal to or more than 1 g/dL in the absence of any red cell transfusion or ESA treatment

    Time frame: Baseline until end of study (week 8)

  4. Subjects receiving red blood cell transfusions or subjects treated with ESA

    Proportion of subjects receiving red blood cell transfusions or subjects treated with ESA during the study period

    Time frame: Baseline until end of study (week 8)

  5. Adverse events

    Adverse events: type, nature, incidence and outcome

    Time frame: Baseline until end of study (week 8)

  6. Transfusion/treatment with ESA

    Time to transfusion/treatment with ESA

    Time frame: Baseline until end of study (week 8)

  7. Change in serum ferritin from baseline to Weeks 2, 4, 6 and 8

    Mean change in serum ferritin from baseline to Weeks 2, 4, 6 and 8

    Time frame: week 2, 4, 6, and 8 post baseline

  8. Change in transferrin saturation (TSAT) from baseline to Weeks 2, 4, 6 and 8

    Mean change in TSAT from baseline to Weeks 2, 4, 6 and 8

    Time frame: week 2, 4, 6, and 8 post baseline

  9. Change in serum iron from baseline to Weeks 2, 4, 6 and 8

    Mean change in serum iron from baseline to Weeks 2, 4, 6 and 8

    Time frame: week 2, 4, 6, and 8 post baseline

  10. Change in endogenous erythropoietin from baseline to Weeks 2, 4, 6 and 8

    Mean change in endogenous erythropoietin from baseline to Weeks 2, 4, 6 and 8

    Time frame: week 2, 4, 6, and 8 post baseline

  11. Change in blood reticulocyte haemoglobin content/red blood cell size factor from baseline to Weeks 2, 4, 6 and 8

    Mean change in blood reticulocyte haemoglobin content/red blood cell size factor from baseline to Weeks 2, 4, 6 and 8

    Time frame: week 2, 4, 6, and 8 post baseline

  12. Change in percentage of hypochromic red cells/percentage of low Hb density from baseline to Weeks 2, 4, 6 and 8

    Mean change in percentage of hypochromic red cells/percentage of low Hb density from baseline to Weeks 2, 4, 6 and 8

    Time frame: week 2, 4, 6, and 8 post baseline

  13. Change in hepcidin from baseline to Weeks 2, 4, 6 and 8

    Mean change in hepcidin from baseline to Weeks 2, 4, 6 and 8

    Time frame: week 2, 4, 6, and 8 post baseline

  14. Change in interleukin-6 from baseline to Weeks 2, 4, 6 and 8

    Mean change in interleukin-6 from baseline to Weeks 2, 4, 6 and 8

    Time frame: week 2, 4, 6, and 8 post baseline

07

Study locations

2 sites
  • Hopital Sud
    Rennes, 35203, France
  • Theagenion Cancer Center
    Thessaloniki, 54007, Greece
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2010, a primary completion of Jul 2011 and a completion of Oct 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 29, 2010
First posted
Apr 9, 2010
Start
Mar 2010
Primary completionActual
Jul 2011
CompletionActual
Oct 2011
Last update
May 9, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 9, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01100879
Lead sponsor
Vifor Pharma
Responsible party
Sponsor
First posted
Apr 9, 2010
Start date
Mar 2010
Primary completion
Jul 2011
Completion
Oct 2011
Last update
May 9, 2022

Study contacts

Katodritou Eirini, MD
principal investigator · Theagenion Hospital, Thessaloniki, Greece
Timothy R Cushway
study director · Vifor Pharma, CH-8152 Glattbrugg, Switzerland

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ferric carboxymaltose

Start the discussion